Elutia Inc. (ELUT)
2.22
-0.11 (-4.72%)
Apr 28, 2025, 12:20 PM - Market open
-4.72% (1D)
| Bid | 2.2 |
| Market Cap | 81.15M |
| Revenue (ttm) | 24.38M |
| Net Income (ttm) | -53.95M |
| EPS (ttm) | -1.86 |
| PE Ratio (ttm) | -1.19 |
| Forward PE | -4.47 |
| Analyst | Strong Buy |
| Ask | 2.32 |
| Volume | 6,661 |
| Avg. Volume (20D) | 42,645 |
| Open | 2.35 |
| Previous Close | 2.33 |
| Day's Range | 2.22 - 2.40 |
| 52-Week Range | 1.87 - 5.24 |
| Beta | 0.96 |
About ELUT
Elutia Inc., a commercial-stage company, develops and commercializes drug-eluting biologics products for neurostimulation, wound care, and breast reconstruction in the United States. The company operates in three segments: Device Protection; Women's Health; and Cardiovascular. It offers CanGaroo Envelope, which is used to accommodate cardiac implantable electronic devices, such as pacemakers and internal defibrillators. The company also develops ...
Industry Biotechnology
Sector Healthcare
IPO Date Oct 8, 2020
Employees 51
Stock Exchange NASDAQ
Ticker Symbol ELUT
Website https://elutia.com
Analyst Forecast
According to 2 analyst ratings, the average rating for ELUT stock is "Strong Buy." The 12-month stock price forecast is $9, which is an increase of 305.41% from the latest price.
Stock ForecastsNext Earnings Release
Elutia Inc. is scheduled to release its earnings on May 12, 2025,
during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
2 months ago
-14.29%
Elutia shares are trading lower after the company ...
Unlock content with
Pro Subscription
10 months ago
-16.97%
Elutia shares are trading lower after the company announced a $13.26 million registered direct offering.
